StockNews.com Begins Coverage on NanoViricides (NYSE:NNVC)

Research analysts at StockNews.com assumed coverage on shares of NanoViricides (NYSE:NNVCGet Free Report) in a research note issued on Sunday. The brokerage set a “sell” rating on the stock.

NanoViricides Price Performance

NNVC stock opened at $1.11 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 7.53 and a quick ratio of 7.53. The firm has a market capitalization of $12.84 million, a P/E ratio of -1.42 and a beta of 0.68. The business’s 50-day moving average is $1.10 and its two-hundred day moving average is $1.22. NanoViricides has a 1 year low of $1.00 and a 1 year high of $2.00.

NanoViricides (NYSE:NNVCGet Free Report) last posted its quarterly earnings results on Tuesday, November 14th. The company reported ($0.17) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On NanoViricides

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of NanoViricides by 7.1% during the 3rd quarter. Vanguard Group Inc. now owns 458,072 shares of the company’s stock worth $792,000 after acquiring an additional 30,194 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of NanoViricides by 10.6% during the 2nd quarter. Renaissance Technologies LLC now owns 78,600 shares of the company’s stock worth $90,000 after acquiring an additional 7,506 shares in the last quarter. Millennium Management LLC raised its position in shares of NanoViricides by 59.1% during the 4th quarter. Millennium Management LLC now owns 67,346 shares of the company’s stock worth $75,000 after acquiring an additional 25,012 shares in the last quarter. Two Sigma Investments LP acquired a new stake in shares of NanoViricides during the 3rd quarter worth about $59,000. Finally, Two Sigma Securities LLC acquired a new stake in shares of NanoViricides during the 2nd quarter worth about $28,000. Institutional investors and hedge funds own 10.61% of the company’s stock.

About NanoViricides

(Get Free Report)

NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.

See Also

Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.